OM240816C3000
- 1.14
- 0.000.00%
Outset Medical Newsroom
Outset Medical up 15% Following Upgrade From RBC Capital Markets
Outset Medical Analyst Ratings
RBC Upgrades Outset Medical to Outperform From Sector Perform, Raises Price Target to $6 From $5
Analysts' Top Healthcare Picks: Outset Medical (OM), Cytokinetics (CYTK)
Bank of America Securities Remains a Sell on Outset Medical (OM)
Morgan Stanley Lowers Price Target on Outset Medical to $4.50 From $5.50, Keeps Equalweight Rating
Oppenheimer Sticks to Their Hold Rating for Outset Medical (OM)
RBC Capital Sticks to Its Hold Rating for Outset Medical (OM)
Outset Medical Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Outset Medical (OM), Exact Sciences (EXAS) and DarioHealth (DRIO)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Crispr Therapeutics AG (CRSP), Alcon (ALC) and Outset Medical (OM)
Outset Medical Downgraded at RBC Citing a Difficult 2024
RBC Capital Downgrades Outset Medical to Sector Perform, Lowers Price Target to $6
Outset Medical Analyst Ratings
Outset Medical Analyst Ratings
Outset Medical's Stable Growth and Financial Consistency: A Buy Rating Recommendation
Morgan Stanley Maintains Equal-Weight on Outset Medical, Lowers Price Target to $5
Outset Medical Analyst Ratings
RBC Capital Reaffirms Their Buy Rating on Outset Medical (OM)
Analysts Conflicted on These Healthcare Names: Ascend Wellness Holdings LLC (OtherAAWH), Vertex Pharmaceuticals (VRTX) and Outset Medical (OM)